Modalis Therapeutics Corporation AI Stock Analysis
Want to see JP:4883 full AI Analyst Report?
Modalis Therapeutics Corporation (4883) AI Stock Analysis
Modalis Therapeutics Corporation
(TSE/TYO:4883)
The overall score of 45.5 reflects a high-risk, pre-revenue biotechnology company. The most significant factor is the weak financial performance, characterized by no revenue, substantial net losses, and a high cash burn rate that is eroding the company's debt-free balance sheet. Technical analysis shows the stock in a longer-term downtrend despite a recent short-term bounce. Traditional valuation metrics are inapplicable due to negative earnings. The company's future is entirely dependent on the success of its clinical programs and its ability to secure additional funding.
Modalis Therapeutics Corporation (4883) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 3.48B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.80M
- Price to Earnings (P/E)
- -1.5
- Beta (1Y)
- 0.89
- Revenue Growth
- ―
- EPS Growth
- 25.34%
- Country
- Japan
- Employees
- 17
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Modalis Therapeutics Corporation Business Overview & Revenue Model
Company Description
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic mod...
How the Company Makes Money
Modalis Therapeutics primarily seeks to generate revenue through the development and monetization of its drug discovery platform and pipeline. Potential revenue streams for a clinical-stage biotech of this type typically include (i) upfront payments,...
Modalis Therapeutics Corporation Financial Statement Overview
Summary
Financial performance is weak, typical of a pre-revenue biotech. The Income Statement (Score 15) shows no revenue and widening losses. The Cash Flow Statement (Score 10) reflects a high and increasing cash burn. The Balance Sheet (Score 35) is a relative strength with no debt, but equity is eroding. The overall financial health is precarious, heavily dependent on future funding.
Income Statement
15Very NegativeBalance Sheet
35NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 40.50M | 1.10M |
| Gross Profit | 0 | 0 | 0 | -731.00K | -83.17M | 1.10M |
| EBITDA | -2.17B | -2.21B | -2.15B | -2.37B | -2.58B | -667.55M |
| Net Income | -2.05B | -2.15B | -1.32B | -2.39B | -2.70B | -738.96M |
Balance Sheet | ||||||
| Total Assets | 3.14B | 2.96B | 3.69B | 2.03B | 3.13B | 6.07B |
| Cash, Cash Equivalents and Short-Term Investments | 3.02B | 2.81B | 3.58B | 1.88B | 2.93B | 4.94B |
| Total Debt | 270.00M | 0 | 0 | 412.50M | 0 | 0 |
| Total Liabilities | 673.71M | 170.94M | 143.47M | 645.50M | 188.60M | 519.92M |
| Stockholders Equity | 2.46B | 2.79B | 3.55B | 1.38B | 2.94B | 5.55B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -2.12B | -1.43B | -2.29B | -2.09B | -854.58M |
| Operating Cash Flow | 0 | -2.12B | -1.43B | -2.25B | -1.90B | -747.47M |
| Investing Cash Flow | 0 | -2.57M | -188.00K | -39.70M | -185.72M | 171.56M |
| Financing Cash Flow | 0 | 1.35B | 3.04B | 1.22B | 63.68M | 72.63M |
Modalis Therapeutics Corporation Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4883, the sentiment is Neutral. The current price of 30.00 is above the 20-day moving average (MA) of 28.00, below the 50-day MA of 31.00, and below the 200-day MA of 43.79, indicating a neutral trend. The MACD of -0.77 indicates Negative momentum. The RSI at 53.97 is Neutral, neither overbought nor oversold. The STOCH value of 79.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4883.
Modalis Therapeutics Corporation Peers Comparison
Overall Rating
JP:457469Neutral
JP:453946.5Neutral- JP:488345.5Neutral
JP:489242Neutral
JP:459739Underperform
JP:458238Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4574 | 69Neutral | JPY 13.27B | 19.21 | ― | 1.25% | 13.30% | 66.38% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4539 | 47Neutral | JPY 5.52B | -11.50 | ― | 3.30% | 0.31% | -194.72% |
| JP:4883 | 46Neutral | JPY 3.13B | -1.45 | ― | ― | ― | 25.34% |
| JP:4892 | 42Neutral | JPY 5.30B | -6.32 | ― | ― | 364.72% | 18.43% |
| JP:4597 | 39Underperform | JPY 6.55B | -8.22 | -53.67% | ― | 109.82% | 61.98% |
| JP:4582 | 38Underperform | JPY 5.25B | -0.65 | ― | ― | -30.58% | 6.93% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4883 | Modalis Therapeutics Corporation | 30.00 | -37.00 | -55.22% | |
| JP:4597 | Solasia Pharma KK | 25.00 | -8.00 | -24.24% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1515.00 | 34.18 | 2.31% | |
| JP:4574 | Taiko Pharmaceutical Co., Ltd. | 263.00 | -27.00 | -9.31% | |
| JP:4582 | Symbio Pharmaceuticals Limited | 59.00 | -47.00 | -44.34% | |
| JP:4892 | Cyfuse Biomedical K.K. | 514.00 | -67.00 | -11.53% |
Modalis Therapeutics Corporation Corporate Events
Modalis Designates Exercise Suspension for 19th Series Rights
Modalis Therapeutics Corporation is listed on the Tokyo Stock Exchange under code 4883. It notified EVO FUND, the allottee of its 19th Series stock acquisition rights, that it designated an exercise suspension period from November 19 through December...
Modalis: 5 Million Yen Foreign-Exchange Gain Recorded
Modalis Therapeutics Corporation recorded 5 million yen in foreign-exchange gains as non-operating income for the nine months ended September 30, 2026. The gains arose mainly from foreign-currency-denominated assets and liabilities held by the Group....
Modalis Therapeutics’ Third-Quarter 2026 Business and Financial Report
Modalis Therapeutics Corporation is identified with TSE ticker 4883, but the release text provided does not describe its industry, products, services, or market focus. The document is titled the company’s third-quarter 2026 business and financial rep...
Modalis Reports Nine-Month 2026 Financial Results
For the nine months ended September 30, 2026, Modalis Therapeutics Corporation reported operating revenue as “-,” an operating loss of ¥1,686 million compared with ¥1,815 million a year earlier, and a loss attributable to owners of the parent of ¥1,6...
Modalis Therapeutics Issues Further Corrections to Interim Financial Results
Modalis Therapeutics Corporation announced further corrections to its consolidated financial results for the six months ended June 30, 2026, under Japanese GAAP. The adjustments affect explanatory materials linked to second-quarter balance sheet, fin...
Modalis Revises Interim Results After R&D Expense Timing Error
Modalis Therapeutics Corporation reported consolidated financial results for the six months ended June 30, 2026, under Japanese GAAP, showing continued operating losses, negative ordinary income, and a basic loss per share, but maintaining a solid eq...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026